Table 2.
Item3 | Arg dosage (mg/egg) | Pooled SEM | P-value | ||||||
---|---|---|---|---|---|---|---|---|---|
NC1 | SC2 | 2 | 6 | 10 | ANOVA | Linear | Quadratic | ||
d 0 to 14 | |||||||||
ADG, g | 6.14 | 6.40 | 6.35 | 6.29 | 6.56 | 0.07 | 0.451 | 0.757 | 0.568 |
ADFI, g | 11.45 | 12.11 | 11.55 | 11.60 | 11.85 | 0.12 | 0.410 | 0.109 | 0.279 |
F/G | 1.87 | 1.90 | 1.82 | 1.82 | 1.87 | 0.02 | 0.500 | 0.442 | 0.714 |
d 15 to 21 | |||||||||
ADG, g | 7.86b | 7.62b | 7.62b | 7.70b | 8.56a | 0.10 | 0.011 | 0.021 | 0.032 |
ADFI, g | 19.42b | 19.62b | 19.19b | 19.72b | 20.82a | 0.16 | 0.019 | 0.037 | 0.044 |
F/G | 2.53 | 2.58 | 2.49 | 2.50 | 2.41 | 0.02 | 0.213 | 0.622 | 0.535 |
d 0 to 21 | |||||||||
ADG, g | 6.45b | 6.71ab | 6.69ab | 6.72ab | 7.00a | 0.06 | 0.030 | 0.073 | 0.143 |
ADFI, g | 13.80b | 14.61a | 14.25ab | 14.02ab | 14.66a | 0.11 | 0.021 | 0.847 | 0.075 |
F/G | 2.14a | 2.14a | 2.13a | 2.08b | 2.07b | 0.01 | 0.016 | 0.047 | 0.032 |
d 22 to 42 | |||||||||
ADG, g | 12.23 | 12.65 | 12.55 | 12.86 | 12.52 | 0.09 | 0.228 | 0.869 | 0.647 |
ADFI, g | 32.30 | 32.37 | 32.80 | 33.49 | 33.00 | 0.22 | 0.075 | 0.545 | 0.284 |
F/G | 2.62 | 2.61 | 2.62 | 2.61 | 2.64 | 0.01 | 0.957 | 0.581 | 0.833 |
d 0 to 42 | |||||||||
ADG, g | 9.28 | 9.55 | 9.51 | 9.55 | 9.58 | 0.05 | 0.400 | 0.509 | 0.826 |
ADFI, g | 22.49 | 22.67 | 22.25 | 23.16 | 23.05 | 0.15 | 0.291 | 0.395 | 0.427 |
F/G | 2.45 | 2.42 | 2.40 | 2.41 | 2.41 | 0.01 | 0.564 | 0.717 | 0.935 |
a–bMeans within a row with no common superscripts differ significantly (P < 0.05). Data are the mean of 8 replicates. 1NC, non-injected control group; 2SC, saline-injected control group. 3ADG, average daily gain; ADFI, average daily feed intake; F/G, feed conversion ratio (feed: gain, g: g). Orthogonal polynomial contrasts were used to determine the linear and quadratic effects of increasing concentrations of L-arginine solution